Women's screening: standards, recommendations, benefits
DOI:
https://doi.org/10.15574/HW.2025.5(180).5460Keywords:
women's screening, prevention, early diagnosis, cancer prevention, cardiovascular diseases, metabolic disorders, standardsAbstract
Women's health is a strategic indicator of the state of public health, demographic stability and socio-economic development of society. It determines not only fertility and life expectancy indicators, but also forms the basis for the sustainable development of the state and the well-being of future generations. Given the global trends of population aging, urbanization and lifestyle changes, the preventive focus of medical care is gaining priority. In the context of the growing prevalence of chronic non-communicable, oncological, endocrine, and metabolic diseases, preventive measures aimed at early detection of pathology are becoming particularly relevant. Women's health screening as a system of periodic examinations allows for the diagnosis of diseases at preclinical stages, reducing mortality and improving the quality of life. At the same time, the level of coverage of screening programs remains insufficient due to low awareness of the population, socio-economic barriers and organizational difficulties in the functioning of the healthcare system.
Aim - to analyze modern standards of female screening, summarize international and national recommendations for preventive examinations and determine their role in increasing the effectiveness of early diagnosis and reducing morbidity and mortality rates.
The study is analytical and review in nature. Scientific publications, clinical guidelines and regulatory documents for 2019-2025 were analyzed. Methods of systemic, comparative and general analysis were used, taking into account age characteristics, individual risk factors and the possibilities of adapting international standards to the national context. It was established that female screening covers oncological, cardiovascular and metabolic, gynecological, hormonal, osteoporotic, and infectious areas. Regular cytological and HPV testing, mammography, as well as monitoring of blood pressure, glycemia and lipid profile ensure timely detection of pathological changes and prevention of complications. For Ukraine, it is relevant to implement a risk-oriented comprehensive screening algorithm integrated into the primary health care system, with subsequent monitoring and increasing women's adherence to preventive examinations.
Conclusion. Women's screening is an effective prevention tool that requires improving organizational mechanisms, strengthening educational work and an individualized approach at different stages of a woman's life.
The authors declare no conflicts of interest.
References
Aguiar-Ibáñez R, Mbous Y, Sharma S, Chakali R, Chawla E. (2025). Barriers to cancer screening uptake and approaches to overcome them: a systematic literature review. Front Oncol. 15: 1575820. https://doi.org/10.3389/fonc.2025.1575820; PMid:40842583 PMCid:PMC12364675
Bernstein E, Lev-Ari S, Shapira S, Leshno A, Sommer U, Al-Shamsi H et al. (2023). Data From a One-Stop-Shop Comprehensive Cancer Screening Center. J Clin Oncol. 41(14): 2503-2510. https://doi.org/10.1200/JCO.22.00938; PMid:36669135
Gavinski K, DiNardo D. (2023). Cervical Cancer Screening. Med Clin North Am. 107(2): 259-269. https://doi.org/10.1016/j.mcna.2022.10.006; PMid:36759096
Hijrah H, Usman AN, Sanusi Baso Y, Syarif S, Ahmad M, Nulandari Z. (2024). Influence of variables on breast self-examination: Potential barrier or enhancement of breast cancer prevention. Breast Disease. 43(1): 145-155. https://doi.org/10.3233/BD-249001; PMid:38820008 PMCid:PMC11191488
Karavska A, Kizub D, Dzhemiliev A, Wanis K, Vus V, Kopetskyi V et al. (2024). Fac-tors Affecting Breast Cancer Screening in Ukraine. JCO Glob Oncol. 10(1): 75-76. https://doi.org/10.1200/GO-24-65000
Lebedyuk VV. (2024). Management of patients with abnormal screening results and precancerous conditions of the cervix according to national standards 2024 (clinical case). Ukrainian Journal Health of Woman. 6(175): 83-88. https://doi.org/10.15574/HW.2024.6(175).8388
Mills JM, Morgan JR, Dhaliwal A, Perkins RB. (2021). Eligibility for cervical cancer screening exit: Comparison of a national and safety net cohort. Gynecol Oncol. 162(2): 308-314. https://doi.org/10.1016/j.ygyno.2021.05.035; PMid:34090706
Mondragón Márquez LI, Domínguez Bueso DL, González Ruiz LM, Liu JJ. (2023). Associations between sociodemographic factors and breast, cervical, and colorectal cancer screening in the United States. Cancer Causes Control. 34(12): 1073-1084. https://doi.org/10.1007/s10552-023-01758-z; PMid:37486400
Narayan AK, Miles RC, Woods RW, Spalluto LB, Burnside ES. (2024). Methodological Considerations in Evaluating Breast Cancer Screening Studies. J Breast Imaging. 6(6): 577-585. https://doi.org/10.1093/jbi/wbae038; PMid:39096512
Nicholson WK, Silverstein M, Wong JB, Chelmow D, Coker TR, Davis EM et al. (2025). Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. JAMA. 333(6): 498-508. https://doi.org/10.1001/jama.2024.27154; PMid:39808425
Ponzel NI. (2025). Validation of the Ukrainian questionnaire "Assessment of Patient Readiness for Breast and Cervical Cancer Screening". Family Medicine. European practices. 2: 54-58. https://doi.org/10.30841/2786-720X.2.2025.331927
Radzishevska YeB, Sukhina OM, Vasylyev LYa, Sukhin VS, Nemaltsova KV, Hranovska HI et al. (2024). Determination of risk factors for the occurrence of recurrences, metastases, and somatic complications after treatment of locally advanced cervical cancer using modern information technologies. Ukrainian journal of radiology and oncology. 32(4): 478-490. https://doi.org/10.46879/ukroj.4.2024.478-490
Rajaram S, Gupta B. (2021). Screening for cervical cancer: Choices & dilemmas. Indian J Med Res. 154(2): 210-220. https://doi.org/10.4103/ijmr.IJMR_857_20; PMid:34854432 PMCid:PMC9131755
Sabatino SA, Thompson TD, White MC, Villarroel MA, Shapiro JA, Croswell JM et al. (2023). Up-to-Date Breast, Cervical, and Colorectal Cancer Screening Test Use in the United States, 2021. Prev Chronic Dis. 20: E94. https://doi.org/10.5888/pcd20.230071; PMid:37884318 PMCid:PMC10625435
Sahasrabuddhe VV. (2024). Cervical Cancer: Precursors and Prevention. Hematol Oncol Clin North Am. 38(4): 771-781. https://doi.org/10.1016/j.hoc.2024.03.005; PMid:38760198
Salingaros S, Shieh Y, Finkel ML, Polaneczky M, Korenstein D, Marti JL. (2024). Public cervical cancer screening recommendations from US cancer centers: Assessing adherence to national guidelines. J Med Screen. 31(3): 201-204. https://doi.org/10.1177/09691413241238960; PMid:38504656
Sefuthi T, Nkonki L. (2022). A systematic review of economic evaluations of cervical cancer screening methods. Syst Rev. 11(1): 162. https://doi.org/10.1186/s13643-022-02017-z; PMid:35945642 PMCid:PMC9361672
Serrano B, Ibáñez R, Robles C, Peremiquel-Trillas P, de Sanjosé S, Bruni L. (2022). Worldwide use of HPV self-sampling for cervical cancer screening. Prev Med. 154: 106900. https://doi.org/10.1016/j.ypmed.2021.106900; PMid:34861338
Shami S, Coombs J. (2021). Cervical cancer screening guidelines: An update. JAAPA. 34(9): 21-24. https://doi.org/10.1097/01.JAA.0000769656.60157.95; PMid:34448772
Simms KT, Keane A, Nguyen DTN, Caruana M, Hall MT, Lui G et al. (2023). Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population. Nat Med. 29(12): 3050-3058. https://doi.org/10.1038/s41591-023-02600-4; PMid:38087115 PMCid:PMC10719104
Svintsitskyi VS, Pryimak VV, Renkas OP. (2020). Modern approaches of the diagnostics and treatment of cervical cancer. Ukrainian Medical Journal. 2(3): 1-7. https://doi.org/10.32471/umj.1680-3051.137.178064
Tokar P. (2025). Indicators of primary detection, staging and dispensary registration of cervical cancer in Ukraine (2014-2023): epidemiological and regional analysis. Health & Education. 3: 90-100. https://doi.org/10.32782/health-2025.3.10
Viveros-Carreño D, Fernandes A, Pareja R. (2023). Updates on cervical cancer prevention. Int J Gynecol Cancer. 33(3): 394-402. https://doi.org/10.1136/ijgc-2022-003703; PMid:36878567
Yezhova IE, Volodko NA. (2025). Clinical, morphological and molecular markersin the formation of prognosis in patientswith cervical cancer: literature review. Reproductive endocrinology. 6: 43-58. doi: 10.18370/2309-4117.2025.81.43-58.
Zafar N, Wolf AB, Kepniss JL, Teal AC, Brem RF. (2024). Effectiveness of Community Education for Breast Cancer Screening. J Breast Imaging. 6(2): 166-174. https://doi.org/10.1093/jbi/wbae002; PMid:38412358
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ukrainian Journal Health of Woman
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal UKRAINIAN JOURNAL «HEALTH OF WOMAN» is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal UKRAINIAN JOURNAL «HEALTH OF WOMAN» when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
